Allison Watson
Hematology & Oncology · Sioux Falls, SDNPI 1750709739
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $225 of the $254 with a category attached, or 88.5%. Novartis accounts for 88.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in SD, where the typical reported total is $811.
Across 2 payments — averaging $127.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$225
- Tempus AI, Inc$29
Across 10 payments — averaging $26,457 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$143K
- E.r. Squibb & Sons, L.L.C.$104K
- Novartis$17K
- Eli Lilly$849
What the payments were for
- Speaking & faculty fees$22588%
- Food & beverage$2912%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $225 |
| Tempus AI, Inc | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$225
How this compares
$254 in reported general payments places this provider in the 35th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 13 | $283,840 |
| VenclextaVenetoclax | 20 | $175,819 |
| EliquisApixaban | 22 | $13,416 |
| XareltoRivaroxaban | 13 | $7,539 |
| Imatinib Mesylate | 35 | $7,267 |
| Abiraterone Acetate | 13 | $3,706 |
| Tamoxifen Citrate | 72 | $1,787 |
| Anastrozole | 67 | $1,471 |
| Prochlorperazine Maleate | 75 | $1,295 |
| Fluconazole | 21 | $1,233 |
| Letrozole | 61 | $1,149 |
| Hydroxyurea | 47 | $1,125 |
| Dexamethasone | 100 | $477 |
| Acyclovir | 40 | $417 |
| LoperamideLoperamide Hcl | 15 | $364 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Sioux Falls
- Kelly McCaulSioux Falls$1.2M
- Roberto Ferro ValdesSioux Falls$142K
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Mark HuberSioux Falls$1K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.